Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Biogen Inc. (BIIB) shares fell 2.67% to $197.74 on Wednesday, underperforming competitors like Johnson & Johnson and Pfizer during a generally weak market session. The stock closed 10% below its 52-week high of $219.72. Trading volume was significantly lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Biogen Inc. (BIIB) slid 2.67% to $197.74 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.14% to 7,498.96 and Dow Jones Industrial Average falling 0.01% to 52,218.58.
Biogen Inc. closed 10.00% short of its 52-week high of $219.72, which the company reached on June 29th.
The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) rose 2.00% to $255.63, Pfizer Inc. (PFE) fell 0.48% to $24.82, and AbbVie Inc. (ABBV) fell 1.09% to $253.30.
Trading volume (840,957) remained 466,628 below its 50-day average volume of 1.3 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 22, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-22-26 1656ET